PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.

doi:10.1007/s11095-021-03095-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.

Pharmaceutical research - 1 Sept 2021

Balhara Ankit, Singh Saranjit

Abstract excerpt

PURPOSE: Isoniazid (INH) is prescribed both for the prophylaxis as well as the treatment of tuberculosis. It is primarily metabolized through acetylation by a highly polymorphic enzyme, N-acetyl transferase 2 (NAT2), owing to which significant variable systemic drug levels have been reported among slow and rapid acetylators. Furthermore, many drugs, like phenytoin, diazepam, triazolam, etc., are known to show...

Topics

Acetylation
Adult
Aged
Antitubercular Agents
Arylamine N-Acetyltransferase
Cytochrome P-450 CYP2C19
Cytochrome P-450 CYP3A
Drug Interactions
Female
Genotype
Humans
Isoniazid
Male
Middle Aged
Polymorphism, Genetic
Prospective Studies
Tuberculosis

Source

Open in PubMed

Identifiers

PMID: 34518943
DOI: 10.1007/s11095-021-03095-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics